217 related articles for article (PubMed ID: 15128744)
1. The intrinsic threshold of the fibrinolytic system is modulated by basic carboxypeptidases, but the magnitude of the antifibrinolytic effect of activated thrombin-activable fibrinolysis inhibitor is masked by its instability.
Walker JB; Bajzar L
J Biol Chem; 2004 Jul; 279(27):27896-904. PubMed ID: 15128744
[TBL] [Abstract][Full Text] [Related]
2. Generation and characterization of a highly stable form of activated thrombin-activable fibrinolysis inhibitor.
Marx PF; Havik SR; Marquart JA; Bouma BN; Meijers JC
J Biol Chem; 2004 Feb; 279(8):6620-8. PubMed ID: 14660622
[TBL] [Abstract][Full Text] [Related]
3. Thrombin-activable fibrinolysis inhibitor zymogen does not play a significant role in the attenuation of fibrinolysis.
Foley JH; Kim P; Nesheim ME
J Biol Chem; 2008 Apr; 283(14):8863-7. PubMed ID: 18252711
[TBL] [Abstract][Full Text] [Related]
4. Complete inhibition of fibrinolysis by sustained carboxypeptidase B activity: the role and requirement of plasmin inhibitors.
Walker JB; Bajzar L
J Thromb Haemost; 2007 Jun; 5(6):1257-64. PubMed ID: 17389009
[TBL] [Abstract][Full Text] [Related]
5. Reversible inhibitors of TAFIa can both promote and inhibit fibrinolysis.
Schneider M; Nesheim M
J Thromb Haemost; 2003 Jan; 1(1):147-54. PubMed ID: 12871552
[TBL] [Abstract][Full Text] [Related]
6. Roles of thermal instability and proteolytic cleavage in regulation of activated thrombin-activable fibrinolysis inhibitor.
Boffa MB; Bell R; Stevens WK; Nesheim ME
J Biol Chem; 2000 Apr; 275(17):12868-78. PubMed ID: 10777585
[TBL] [Abstract][Full Text] [Related]
7. Generation of a stable activated thrombin activable fibrinolysis inhibitor variant.
Ceresa E; Van de Borne K; Peeters M; Lijnen HR; Declerck PJ; Gils A
J Biol Chem; 2006 Jun; 281(23):15878-83. PubMed ID: 16595693
[TBL] [Abstract][Full Text] [Related]
8. Stabilization versus inhibition of TAFIa by competitive inhibitors in vitro.
Walker JB; Hughes B; James I; Haddock P; Kluft C; Bajzar L
J Biol Chem; 2003 Mar; 278(11):8913-21. PubMed ID: 12643276
[TBL] [Abstract][Full Text] [Related]
9. A study of the mechanism of inhibition of fibrinolysis by activated thrombin-activable fibrinolysis inhibitor.
Wang W; Boffa MB; Bajzar L; Walker JB; Nesheim ME
J Biol Chem; 1998 Oct; 273(42):27176-81. PubMed ID: 9765237
[TBL] [Abstract][Full Text] [Related]
10. The profibrinolytic effect of activated protein C in clots formed from plasma is TAFI-dependent.
Bajzar L; Nesheim ME; Tracy PB
Blood; 1996 Sep; 88(6):2093-100. PubMed ID: 8822928
[TBL] [Abstract][Full Text] [Related]
11. Thrombin activatable fibrinolysis inhibitor (TAFI) affects fibrinolysis in a plasminogen activator concentration-dependent manner. Study of seven plasminogen activators in an internal clot lysis model.
Guimarães AH; Rijken DC
Thromb Haemost; 2004 Mar; 91(3):473-9. PubMed ID: 14983222
[TBL] [Abstract][Full Text] [Related]
12. Plasma and recombinant thrombin-activable fibrinolysis inhibitor (TAFI) and activated TAFI compared with respect to glycosylation, thrombin/thrombomodulin-dependent activation, thermal stability, and enzymatic properties.
Boffa MB; Wang W; Bajzar L; Nesheim ME
J Biol Chem; 1998 Jan; 273(4):2127-35. PubMed ID: 9442053
[TBL] [Abstract][Full Text] [Related]
13. TAFIa, PAI-1 and alpha-antiplasmin: complementary roles in regulating lysis of thrombi and plasma clots.
Mutch NJ; Thomas L; Moore NR; Lisiak KM; Booth NA
J Thromb Haemost; 2007 Apr; 5(4):812-7. PubMed ID: 17388801
[TBL] [Abstract][Full Text] [Related]
14. Two naturally occurring variants of TAFI (Thr-325 and Ile-325) differ substantially with respect to thermal stability and antifibrinolytic activity of the enzyme.
Schneider M; Boffa M; Stewart R; Rahman M; Koschinsky M; Nesheim M
J Biol Chem; 2002 Jan; 277(2):1021-30. PubMed ID: 11684677
[TBL] [Abstract][Full Text] [Related]
15. Both cellular and soluble forms of thrombomodulin inhibit fibrinolysis by potentiating the activation of thrombin-activable fibrinolysis inhibitor.
Bajzar L; Nesheim M; Morser J; Tracy PB
J Biol Chem; 1998 Jan; 273(5):2792-8. PubMed ID: 9446587
[TBL] [Abstract][Full Text] [Related]
16. A study of the protection of plasmin from antiplasmin inhibition within an intact fibrin clot during the course of clot lysis.
Schneider M; Nesheim M
J Biol Chem; 2004 Apr; 279(14):13333-9. PubMed ID: 14715655
[TBL] [Abstract][Full Text] [Related]
17. Comparative evaluation of stable TAFIa variants: importance of alpha-helix 9 and beta-sheet 11 for TAFIa (in)stability.
Ceresa E; De Maeyer M; Jonckheer A; Peeters M; Engelborghs Y; Declerck PJ; Gils A
J Thromb Haemost; 2007 Oct; 5(10):2105-12. PubMed ID: 17666015
[TBL] [Abstract][Full Text] [Related]
18. Activated thrombin-activatable fibrinolysis inhibitor reduces the ability of high molecular weight fibrin degradation products to protect plasmin from antiplasmin.
Schneider M; Brufatto N; Neill E; Nesheim M
J Biol Chem; 2004 Apr; 279(14):13340-5. PubMed ID: 14715654
[TBL] [Abstract][Full Text] [Related]
19. Role of isoleucine residues 182 and 183 in thrombin-activatable fibrinolysis inhibitor.
Marx PF; Havik SR; Bouma BN; Meijers JC
J Thromb Haemost; 2005 Jun; 3(6):1293-300. PubMed ID: 15946220
[TBL] [Abstract][Full Text] [Related]
20. Insights into thrombin activatable fibrinolysis inhibitor function and regulation.
Foley JH; Kim PY; Mutch NJ; Gils A
J Thromb Haemost; 2013 Jun; 11 Suppl 1():306-15. PubMed ID: 23809134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
